2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines-Reference-Cited by-同舟云学术

2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines

Published:2021-12 Issue:8 Volume:5 Page:
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Othman Maha¹²^ORCID,Favaloro Emmanuel J.³⁴⁵^ORCID

Affiliation:

1. Department of Biomedical and Molecular Sciences School of Medicine Queen’s University Kingston Ontario Canada

2. School of Baccalaureate Nursing St Lawrence College Kingston Ontario Canada

3. Department of Haematology Institute of Clinical Pathology and Medical Research (ICPMR) NSW Health Pathology Westmead Hospital Westmead New South Wales Australia

4. Sydney Centres for Thrombosis and Haemostasis Westmead New South Wales Australia

5. School of Biomedical Sciences Charles Sturt University Wagga Wagga New South Wales Australia

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12635

Reference26 articles.

1. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease

2. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

3. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology

4. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)

5. Evaluating errors in the laboratory identification of von Willebrand disease (VWD) using contemporary von Willebrand factor (VWF) assays;Favaloro EJ;Pathology,2021

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bleeding Disorder of Unknown Cause: A Diagnosis of Exclusion;Hämostaseologie;2024-02-27

2. Letter in response to Othman & Favaloro “Comparison of two ways of performing ristocetin-induced platelet agglutination (RIPA) mixing study for diagnosis of type 2B VWD”;Research and Practice in Thrombosis and Haemostasis;2023-08

3. Comparison of 2 ways of performing ristocetin-induced platelet agglutination mixing study for diagnosis of type 2B von Willebrand disease. Response to the publication of Soleimani et al;Research and Practice in Thrombosis and Haemostasis;2023-07

4. Laboratory diagnosis of von Willebrand disease in the age of the new guidelines: considerations based on geography and resources;Research and Practice in Thrombosis and Haemostasis;2023-07

5. Challenges in the management of women with type 2B von Willebrand disease during pregnancy and the postpartum period: evidence from literature and data from an international registry and physicians’ survey—communication from the Scientific and Standardization Committees of the International Society on Thrombosis and Haemostasis;Journal of Thrombosis and Haemostasis;2023-01